The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โABBVโ.
According to AbbVie's latest financial reports the company's total assets are $134.71 B. A companyโs total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.
Year | Total assets | Change |
---|---|---|
2023-12-31 | $134.71 B | -2.95% |
2022-12-31 | $138.80 B | -5.27% |
2021-12-31 | $146.52 B | -2.68% |
2020-12-31 | $150.56 B | 68.96% |
2019-12-31 | $89.11 B | 50.15% |
2018-12-31 | $59.35 B | -16.15% |
2017-12-31 | $70.78 B | 7.09% |
2016-12-31 | $66.09 B | 24.6% |
2015-12-31 | $53.05 B | 92.82% |
2014-12-31 | $27.51 B | -5.77% |
2013-12-31 | $29.19 B | 8.11% |
2012-12-31 | $27.00 B | 38.35% |
2011-12-31 | $19.52 B | -7.64% |
2010-12-31 | $21.13 B |
Company | Total assets | differencediff. | Country |
---|---|---|---|
Pfizer PFE | $226.50 B | 68.14% | ๐บ๐ธ USA |
Eli Lilly LLY | $63.94 B | -52.53% | ๐บ๐ธ USA |
Amgen AMGN | $97.15 B | -27.88% | ๐บ๐ธ USA |
Biogen BIIB | $26.56 B | -80.28% | ๐บ๐ธ USA |
Gilead Sciences GILD | $62.12 B | -53.88% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | $99.03 B | -26.49% | ๐บ๐ธ USA |
AstraZeneca AZN | $102.29 B | -24.06% | ๐ฌ๐ง UK |
GlaxoSmithKline GSK | $73.94 B | -45.11% | ๐ฌ๐ง UK |
Neurocrine Biosciences
NBIX | $3.47 B | -97.42% | ๐บ๐ธ USA |